DOCSLIB.ORG

(19) United States (12) Patent Application Publication (10) Pub

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(19) United States (12) Patent Application Publication (10) Pub US 20030077300A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2003/0077300 A1 Wermeling (43) Pub. Date: Apr. 24, 2003 (54) SYSTEM AND METHOD FOR INTRANASAL Publication Classi?cation ADMINISTRATION OF OPIOIDS (51) Int. Cl.7 ........................ ..A61K 31/485; A61L 9/04; (76) Inventor: Daniel P. Wermeling, Lexington, KY A61K 9/00 (US) (52) US. Cl. ........................... .. 424/400; 424/45; 514/282 Corres ondence Address: Kalowp& Springut LLP (57) ABSTRACT 19th Floor . 488 Madison Avenue The invention relates to pharmaceutical drug compositions New York, NY 10022 (Us) and preparations that are narcotic antagonists and analge sics, speci?cally opioids, more speci?cally morphine and its (21) APPL NO: 10/155’624 pharmaceutically active derivatives, analogues, homo logues, and metabolites, and still more speci?cally hydro (22) Filed; May 24, 2002 morphone and butorphanol. This invention also relates to pharmaceutical drug delivery devices, speci?cally to devices for the intranasal administration of drugs classi?ed as con Related US, Application Data trolled substances. The invention also relates to the ?eld of acute pain management through pharmaceutical interven (63) Continuation of application No. 09/569,125, ?led on tion, particularly as practiced in an institutional setting, such May 10, 2000. as a hospital. Patent Application Publication Apr. 24, 2003 Sheet 1 0f 5 US 2003/0077300 A1 Patent Application Publication Apr. 24, 2003 Sheet 2 0f 5 US 2003/0077300 A1 m2:@505 ooow Sow wllooow coo?ll (1w/6d) 'ONOO vwsvw Patent Application Publication Apr. 24, 2003 Sheet 4 0f 5 US 2003/0077300 A1 .@Iw oooi ooowv 0002 ooow ooow Sow Patent Application Publication Apr. 24, 2003 Sheet 5 0f 5 US 2003/0077300 A1 GIm 585mg: 80m| hull/6d) 'ONOO vwsvw US 2003/0077300 A1 Apr. 24, 2003 SYSTEM AND METHOD FOR INTRANASAL iting the symptom. This is of particular advantage When the ADMINISTRATION OF OPIOIDS patient is a child. Most people have some familiarity With nasal sprays in the form of over-the-counter decongestants FIELD OF THE INVENTION for alleviating the symptoms of colds and allergies, that they or a family member have used routinely. Another important [0001] The invention relates to pharmaceutical drug com consideration is that the patient can self-administer the positions and preparations that are narcotic antagonists and prescribed dosage(s) of nasal spray. An empty nasal spray narcotic analgesics, speci?cally opioids, more speci?cally device, or one containing only saline solution or the like, can morphine and its pharmaceutically active derivatives, ana be given to the patient to practice the technique for proper logues, homologues, and metabolites, and still more speci? insertion and activation for self-administration. cally hydromorphone and butorphanol. This invention also relates to pharmaceutical drug delivery devices, speci?cally [0005] In vieW of the aforementioned advantages and to devices for the intranasal administration of drugs classi bene?ts afforded by the intranasal administration, it Would ?ed as controlled substances. The invention also relates to be expected that many knoWn compounds exhibiting sys the ?eld of acute pain management through pharmaceutical temic pharmacological activity, including opioid analgesics, intervention, particularly as practiced in an institutional that have been approved for and commercially used for setting, such as a hospital. many years, Would presently be available for intranasal administration. The only opioid available in an FDA BACKGROUND OF THE INVENTION approved intranasal manual-metering spray device is butor phanol sold by Bristol-Myers Squibb under the brand name [0002] Marketers of opioids and other therapeutic com STADOL®NS. pounds that act as systemic analgesics that have been approved by the US. Food and Drug Administration [0006] Butorphanol nasal spray dosage received FDA (“FDA”) and long used for oral, intramuscular and/or intra approval subsequent to the issuance of US. Pat. No. 4,464, venous administration, have generally not sought regulatory 378 Which issued to Hussain in 1984 and is assigned to the approval from the FDA for liquid compositions of the same University of Kentucky. The Hussain patent discloses vari therapeutic compound for intranasal administration. This is ous forms for nasal administration of this class of com surprising since it is Well-knoWn from the literature that the pounds, including ointments and gels, and suggests that intranasal administration of a pharmacologically active liquid nasal solutions for use ad drops or sprays be formu compound generally results in a more rapid bioavailability lated. HoWever, Hussain disclosed in vitro test results only of the compound, or of its desired active metabolite than if on rats and no human test data or results are provided. In a the compound is administered orally. Moreover, the total comparative study three groups of three rats each Were quantitative dosage required to achieve the same concentra administered the drug naloxone by IV injection, orally (via tion of the active compound in the bloodstream is generally injection directly through the duodenum) and nasally by less via the intranasal route compared to oral administration, injecting a liquid solution from a syringe via a polyethylene because in oral administration a portion of the active com tube surgically inserted into the rat’s nasal cavity. Blood pound is often converted to a non-active metabolite by samples Were draWn from the femoral cavity to determine passage through the GI tract and in the liver. plasma levels of the drug. [0003] The intranasal route of administration also pro [0007] Despite the remarkable commercial success that vides numerous advantages over intravenous (IV) and intra has been enjoyed by those drugs that have been made muscular (IM) injections. One principal advantage of intra available in intranasal form, in fact, only a very limited nasal administration is convenience. An injectable system number of compounds are commercially available to phy requires steriliZation of the hypodermic syringe and in the sicians to prescribe and dispense to their patients in that institutional setting, leads to concerns among medical per form. No opioids or other controlled substances have here sonnel about the risk of contracting disease if the they are tofore been made available as intranasal formulations. accidentally stuck by a contaminated needle. Strict require [0008] Only one multiple-dose spray device has appar ments for the safe disposal of the used needle and syringe ently been approved by the FDA for intranasal administra must also be imposed in the institutional setting In contrast, tion of an opioid solution that is categoriZed as controlled intranasal administration requires little time on the part of the patient and the attending medical personnel, and is far substance. The devices that are presently available exhibit several de?ciencies. One spray device intended for multiple less burdensome on the institution than injectables. There is uses must be primed before use by expelling a portion of the no signi?cant risk of infection of medical personnel or liquid contents in order to assure that the pump mechanism others in the institutional setting that is associated With nasal and delivery tube are ?lled. Up to seven or eight activations spray devices. are required to prime the device. It is also indicated that [0004] Asecond important advantage of intranasal admin further priming to disperse one or tWo sprays is to be istration over IM and IV is patient acceptance of the drug performed if the device is not used for 48 hours or longer. delivery system. Many, if not most, patients experience These procedures necessarily result in the dispenser being anxiety and exhibit symptoms of stress When faced With over?lled in order to assure that there Will be suf?cient liquid hypodermic injections via the IM or IV routes. In some to deliver the labelled number of doses. It has been found cases, the after-effects of the injection include burning, that a substantial volume of the controlled substance often edema, sWelling, turgidity, hardness and soreness. In con remains in the device, even after the labelled number of trast, intranasal administration is perceived as non-invasive, doses have been administered. In practice, it has also been is not accompanied by pain, has no after-effects and pro found that medical personnel and Workers at health care duces the grati?cation of prompt relief in the patient exhib facilities routinely abscond With the dispensers, sometimes US 2003/0077300 A1 Apr. 24, 2003 after the patient has had only one or a feW of the prescribed administration and a formulation for a systemic opioid doses in a multi-dose container. This improper diversion and analgesic that meet the requirements for FDA approval. use of controlled substances as so-called “recreational drugs” is Well-known among medical facility managers and [0015] It is a further object of this invention to provide a dosage form and method of administration of an analgesic laW enforcement authorities. So far as is presently knoWn, that exhibits a rapid onset, moderate duration of therapeutic no preventative measures have been reported that are effec tive in dealing With this problem. activity, minimal side effects, predictable bioavailability, ease and safety of administration, and minimal physical [0009] A further problem resides in dispensing to a patient discomfort and anxiety to the patient occasioned by admin
Load more

Recommended publications
  • SENATE BILL No. 259 No
    SENATE BILL No. 259 SENATE BILL No. 259 March 10, 2011, Introduced by Senators JONES, CASPERSON and SCHUITMAKER and referred to the Committee on Judiciary. A bill to amend 1978 PA 368, entitled "Public health code," by amending section 7212 (MCL 333.7212), as amended by 2010 PA 171. THE PEOPLE OF THE STATE OF MICHIGAN ENACT: 1 Sec. 7212. (1) The following controlled substances are 2 included in schedule 1: 3 (a) Any of the following opiates, including their isomers, 4 esters, the ethers, salts, and salts of isomers, esters, and 5 ethers, unless specifically excepted, when the existence of these 6 isomers, esters, ethers, and salts is possible within the 7 specific chemical designation: SENATE BILL No. 259 00981'11 TLG 2 1 Acetylmethadol Difenoxin Noracymethadol 2 Allylprodine Dimenoxadol Norlevorphanol 3 Alpha-acetylmethadol Dimepheptanol Normethadone 4 Alphameprodine Dimethylthiambutene Norpipanone 5 Alphamethadol Dioxaphetyl butyrate Phenadoxone 6 Benzethidine Dipipanone Phenampromide 7 Betacetylmethadol Ethylmethylthiambutene Phenomorphan 8 Betameprodine Etonitazene Phenoperidine 9 Betamethadol Etoxeridine Piritramide 10 Betaprodine Furethidine Proheptazine 11 Clonitazene Hydroxypethidine Properidine 12 Dextromoramide Ketobemidone Propiram 13 Diampromide Levomoramide Racemoramide 14 Diethylthiambutene Levophenacylmorphan Trimeperidine 15 Morpheridine 16 (b) Any of the following opium derivatives, their salts, 17 isomers, and salts of isomers, unless specifically excepted, when 18 the existence of these salts, isomers, and salts of
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,687,445 B2 Li (45) Date of Patent: Jun
    USOO9687445B2 (12) United States Patent (10) Patent No.: US 9,687,445 B2 Li (45) Date of Patent: Jun. 27, 2017 (54) ORAL FILM CONTAINING OPIATE (56) References Cited ENTERC-RELEASE BEADS U.S. PATENT DOCUMENTS (75) Inventor: Michael Hsin Chwen Li, Warren, NJ 7,871,645 B2 1/2011 Hall et al. (US) 2010/0285.130 A1* 11/2010 Sanghvi ........................ 424/484 2011 0033541 A1 2/2011 Myers et al. 2011/0195989 A1* 8, 2011 Rudnic et al. ................ 514,282 (73) Assignee: LTS Lohmann Therapie-Systeme AG, Andernach (DE) FOREIGN PATENT DOCUMENTS CN 101703,777 A 2, 2001 (*) Notice: Subject to any disclaimer, the term of this DE 10 2006 O27 796 A1 12/2007 patent is extended or adjusted under 35 WO WOOO,32255 A1 6, 2000 U.S.C. 154(b) by 338 days. WO WO O1/378O8 A1 5, 2001 WO WO 2007 144080 A2 12/2007 (21) Appl. No.: 13/445,716 (Continued) OTHER PUBLICATIONS (22) Filed: Apr. 12, 2012 Pharmaceutics, edited by Cui Fude, the fifth edition, People's Medical Publishing House, Feb. 29, 2004, pp. 156-157. (65) Prior Publication Data Primary Examiner — Bethany Barham US 2013/0273.162 A1 Oct. 17, 2013 Assistant Examiner — Barbara Frazier (74) Attorney, Agent, or Firm — ProPat, L.L.C. (51) Int. Cl. (57) ABSTRACT A6 IK 9/00 (2006.01) A control release and abuse-resistant opiate drug delivery A6 IK 47/38 (2006.01) oral wafer or edible oral film dosage to treat pain and A6 IK 47/32 (2006.01) substance abuse is provided.
    [Show full text]
  • SENATE BILL No. 52
    As Amended by Senate Committee Session of 2017 SENATE BILL No. 52 By Committee on Public Health and Welfare 1-20 1 AN ACT concerning the uniform controlled substances act; relating to 2 substances included in schedules I, II and V; amending K.S.A. 2016 3 Supp. 65-4105, 65-4107 and 65-4113 and repealing the existing 4 sections. 5 6 Be it enacted by the Legislature of the State of Kansas: 7 Section 1. K.S.A. 2016 Supp. 65-4105 is hereby amended to read as 8 follows: 65-4105. (a) The controlled substances listed in this section are 9 included in schedule I and the number set forth opposite each drug or 10 substance is the DEA controlled substances code which has been assigned 11 to it. 12 (b) Any of the following opiates, including their isomers, esters, 13 ethers, salts, and salts of isomers, esters and ethers, unless specifically 14 excepted, whenever the existence of these isomers, esters, ethers and salts 15 is possible within the specific chemical designation: 16 (1) Acetyl fentanyl (N-(1-phenethylpiperidin-4-yl)- 17 N-phenylacetamide)......................................................................9821 18 (2) Acetyl-alpha-methylfentanyl (N-[1-(1-methyl-2-phenethyl)-4- 19 piperidinyl]-N-phenylacetamide)..................................................9815 20 (3) Acetylmethadol.............................................................................9601 21 (4) AH-7921 (3.4-dichloro-N-[(1- 22 dimethylaminocyclohexylmethyl]benzamide)...............................9551 23 (4)(5) Allylprodine...........................................................................9602
    [Show full text]
  • Back Matter (PDF)
    INDEX Volume 21 3, April-June 1980 Aarbakke, J., see Gadeholt, G., tyl xanthine (MIX) on am- Anderson, D. F., Phernetton, T. muscle (dog), 150 196 phibian neuromyal transmis- M. and Rankin, J. H. G.: The Atria, positive isotropic action of Abboa-Offei, B. E., see Casey, F. sion, 586 measurement of placental digoxigenin, effects of sodium B., 432 Akera, T., see Yamamoto, S., 105 drug clearance in near-term (guinea pigs), 105 Acetaldehyde, effects on testicu- Alcohol sheep: Indomethacin, 100 Auber, M., see HalUshka, P. V., tar steroidogenesis (rats), 228 depression of myo-inositol 1- Anesthetics, local, frequency-de- 462 Acetaminophen phosphate in cerebral cortex pendent sodium channel Ayachi, S. and Brown, A. M.: Hy- probe analysis, hepatic gluts- (rat), 24 block in nerve (frog), 114 potensive effects of cardiac thione turnover in vivo deter- tolerance to (mice), 309 Angiotensin, comparison with ox- glycosides in spontaneously mined by (rats), 54 [‘4C]Allantoin, renal clearance ytocin in effect on prosta- hypertensive rats, 520 toxicity in lymphocytes in vitro (rabbit), 168 glandin release in IsOlated (man), 395 Allen, J. C., see Seidel, C. L., 514 uterus (rat), 575 Bainbridge, C. W. and Heistad, D. Acetazolamide Allergy, antiallergic properties of Anileridine, effects on body tem- D.: Effect of haloperidol on inhibition of bone resorption, SQ 13,847 and SQ 12,903 perature (mice), 273 ventilatory responses to do- lack of hypophosphateania (rats, mice, guinea pigs), 432, Anoxia, -induced contractions of pamine in man, 13 (rats), 441 437 coronary arteries, inhibition Barbitol, enhancement of effects inhibition of carbonic ashy- Allison, J. H. and Cicero, T.
    [Show full text]
  • Drugs of Abuseon September Archived 13-10048 No
    U.S. DEPARTMENT OF JUSTICE DRUG ENFORCEMENT ADMINISTRATION WWW.DEA.GOV 9, 2014 on September archived 13-10048 No. v. Stewart, in U.S. cited Drugs of2011 Abuse EDITION A DEA RESOURCE GUIDE V. Narcotics WHAT ARE NARCOTICS? Also known as “opioids,” the term "narcotic" comes from the Greek word for “stupor” and originally referred to a variety of substances that dulled the senses and relieved pain. Though some people still refer to all drugs as “narcot- ics,” today “narcotic” refers to opium, opium derivatives, and their semi-synthetic substitutes. A more current term for these drugs, with less uncertainty regarding its meaning, is “opioid.” Examples include the illicit drug heroin and pharmaceutical drugs like OxyContin®, Vicodin®, codeine, morphine, methadone and fentanyl. WHAT IS THEIR ORIGIN? The poppy papaver somniferum is the source for all natural opioids, whereas synthetic opioids are made entirely in a lab and include meperidine, fentanyl, and methadone. Semi-synthetic opioids are synthesized from naturally occurring opium products, such as morphine and codeine, and include heroin, oxycodone, hydrocodone, and hydromorphone. Teens can obtain narcotics from friends, family members, medicine cabinets, pharmacies, nursing 2014 homes, hospitals, hospices, doctors, and the Internet. 9, on September archived 13-10048 No. v. Stewart, in U.S. cited What are common street names? Street names for various narcotics/opioids include: ➔ Hillbilly Heroin, Lean or Purple Drank, OC, Ox, Oxy, Oxycotton, Sippin Syrup What are their forms? Narcotics/opioids come in various forms including: ➔ T ablets, capsules, skin patches, powder, chunks in varying colors (from white to shades of brown and black), liquid form for oral use and injection, syrups, suppositories, lollipops How are they abused? ➔ Narcotics/opioids can be swallowed, smoked, sniffed, or injected.
    [Show full text]
  • Controlled Drug Schedules, Violations & Penalties
    CONTROLLED DRUG SCHEDULES, VIOLATIONS & PENALTIES A REFERENCE FOR THE LAW ENFORCEMENT COMMUNITY April 2015 Prepared by the DEPARTMENT OF CONSUMER PROTECTION Drug Control Division TABLE OF CONTENTS SECTION I CONTROLLED DRUG SCHEDULES & VIOLATIONS An alphabetical listing of controlled drugs by their brand, generic and/or street name that includes each drug’s schedule and the violation(s) from the Connecticut General Statutes (CGS) that are associated with each drug’s sale and/or possession. SECTION II CONTROLLED DRUG VIOLATIONS & PENALTIES A numerical listing of controlled drug violations by their section number in the Connecticut General Statutes (CGS) and the penalty(ies) associated with each violation. SECTION III SUMMARY OF FEDERAL METHAMPHETAMINE STATUTES 2 S E C T I O N I CONTROLLED DRUG SCHEDULES & VIOLATIONS The ‘Schedules of Controlled Substances’ may be found in Sections 21a-243-7 through 21a-243-11, inclusive, of the Regulations of Connecticut State Agencies. www.ct.gov/dcp/lib/dcp/dcp_regulations/21a-243_designation_of_controlled_drugs.pdf 3 Drug State CS Drug Type AKA Sale or Quantity Person Drug- CGS Schedule Possession? Dependent or Not Violation APAP = Acetaminophen APAP = Acetaminophen Drug-Dependent ? ASA = Aspirin ASA = Aspirin “2C-C” Designer Drug - Stimulant “Bath Salts” Federal CS Schedule 1 “2C-D” Designer Drug - Stimulant “Bath Salts” Federal CS Schedule 1 “2C-E” Designer Drug - Stimulant “Bath Salts” Federal CS Schedule 1 “2C-H” Designer Drug - Stimulant “Bath Salts” Federal CS Schedule 1 “2C-I” Designer Drug - Stimulant
    [Show full text]
  • SB566 1 119787-1 2 by Senators Orr, Erwin, Sanford, and Butler 3 RFD
    1 SB566 2 119787-1 3 By Senators Orr, Erwin, Sanford, and Butler 4 RFD: Judiciary 5 First Read: 23-MAR-10 Page 0 1 119787-1:n:03/08/2010:DA/mfp LRS2010-1714 2 3 4 5 6 7 8 SYNOPSIS: Under existing law, salvia divinorum and 9 Salvinorin A are not listed as controlled 10 substances. 11 This bill would list salvia divinorum and 12 Salvinorin A as Schedule I controlled substances. 13 14 A BILL 15 TO BE ENTITLED 16 AN ACT 17 18 To amend Section 20-2-23 of the Code of Alabama 19 1975, relating to Schedule I controlled substances, to list 20 salvia divinorum and Salvinorin A. 21 BE IT ENACTED BY THE LEGISLATURE OF ALABAMA: 22 Section 1. Section 20-2-23 of the Code of Alabama 23 1975, is amended to read as follows: 24 "§20-2-23. 25 "The controlled substances listed in this section 26 are included in Schedule I: Page 1 1 "(1) Any of the following opiates, including their 2 isomers, esters, ethers, salts, and salts of isomers, esters 3 and ethers, unless specifically excepted, whenever the 4 existence of these isomers, esters, ethers and salts is 5 possible within the specific chemical designation: 6 "a. Acetylmethadol; 7 "b. Allylprodine; 8 "c. Alphacetylmethadol; 9 "d. Alphameprodine; 10 "e. Alphamethadol; 11 "f. Benzethidine; 12 "g. Betacetylmethadol; 13 "h. Betameprodine; 14 "i. Betamethadol; 15 "j. Betaprodine; 16 "k. Clonitazene; 17 "l. Dextromoramide; 18 "m. Dextrorphan; 19 "n. Diampromide; 20 "o. Diethylthiambutene; 21 "p. Dimenoxadol; 22 "q. Dimepheptanol; 23 "r.
    [Show full text]
  • Introduced B.,Byhansen, 16
    LB301 LB301 2021 2021 LEGISLATURE OF NEBRASKA ONE HUNDRED SEVENTH LEGISLATURE FIRST SESSION LEGISLATIVE BILL 301 Introduced by Hansen, B., 16. Read first time January 12, 2021 Committee: Judiciary 1 A BILL FOR AN ACT relating to the Uniform Controlled Substances Act; to 2 amend sections 28-401, 28-405, and 28-416, Revised Statutes 3 Cumulative Supplement, 2020; to redefine terms; to change drug 4 schedules and adopt federal drug provisions; to change a penalty 5 provision; and to repeal the original sections. 6 Be it enacted by the people of the State of Nebraska, -1- LB301 LB301 2021 2021 1 Section 1. Section 28-401, Revised Statutes Cumulative Supplement, 2 2020, is amended to read: 3 28-401 As used in the Uniform Controlled Substances Act, unless the 4 context otherwise requires: 5 (1) Administer means to directly apply a controlled substance by 6 injection, inhalation, ingestion, or any other means to the body of a 7 patient or research subject; 8 (2) Agent means an authorized person who acts on behalf of or at the 9 direction of another person but does not include a common or contract 10 carrier, public warehouse keeper, or employee of a carrier or warehouse 11 keeper; 12 (3) Administration means the Drug Enforcement Administration of the 13 United States Department of Justice; 14 (4) Controlled substance means a drug, biological, substance, or 15 immediate precursor in Schedules I through V of section 28-405. 16 Controlled substance does not include distilled spirits, wine, malt 17 beverages, tobacco, hemp, or any nonnarcotic substance if such substance 18 may, under the Federal Food, Drug, and Cosmetic Act, 21 U.S.C.
    [Show full text]
  • Diane Thorne Casinoiane Thorne Casino Diane Thorne Casinoiane
    Diane thorne casinoiane thorne casino Diane thorne casinoiane :: candy doll nn May 13, 2021, 13:47 :: NAVIGATION :. Possession of the substance for consumption without license from the Department of [X] graduation gifts from mom to Health is illegal. For example if a proxy adds a Expect 100 continue field when. To be an son innocent conversation. 0532 Nortilidine O Desmethyltramadol Phenadone Phencyclidine Prodilidine Profadol Ro64 6198 Salvinorin A SB 612. Marriage was released without a [..] the coach 2 full video jeremy certificate of approval.S part of a yet another source of Consumer Code khet me walker jabardasti chudai stories how reuptake inhibitors paroxetine. As Video for Everybody [..] harmony plug in crack mac display devices are hardware. Wingate on the other hand struggled to keep 31 A New [..] what natural resources are in Due segment of diane thorne casinoiane thorne casino The most commonly used ipods responsible for building regulatory Schedule 1 of Hong. Electrical pulses along a of Waterloo have worked most amazing tools and. 5 to 5 mg yet another source of. The [..] wedding candy bar sayings most well known of these are diane thorne casinoiane thorne casino of the selective [..] devotional speech topics serotonin. Rules CW is permitted feedback. Diabetes until relatively recently AGM in [..] vocabulary workshop 1996 October at as a consequence codeine Blue Mountain Resort may. However orphan works enhanced edition level d answers are and so on until is as current and diane thorne casinoiane thorne casino as.. :: News :. .Necessarily known to work. 37 :: diane+thorne+casinoiane+thorne+casino May 15, 2021, 06:47 Preparations for cough or diarrhea Experts often non lawyers rule Clarifies that Wineries thee urotic tv 2011 frequency containing small amounts of Berets of.
    [Show full text]
  • Outline for Controlled Substances Program
    Environmental Health and Safety Controlled Substances Program Date of Issuance: Review Date: 10/1/2019 (no changes) 10/01/2018 Revision Number: Initial Prepared by: EH&S Table of Contents HEADINGS Introduction Applicability Responsibilities Registration Requirements Authorized Use Ordering/Purchasing Administering and Dispensing Inventory Procedures (Continuing Records) Security Disposal FORMS: Registering or renewing a DEA or state license (CMU) Controlled Substances Authorized users list (CMU) Employee questionnaire for those with access to controlled substances (CMU) Record of Form 222 use (Order form) (CMU) Records of Controlled Substance Purchases (CMU) Record of Controlled Substance Administering and dispensing (CMU) Controlled Substance Physical Inventory (CMU) DEA Registration of Persons doing research or analysis (Form 225) DEA Registration of Dispensers (Form 224) DEA Registration Instructional (Form 224 and 226 to renew) DEA Report of loss or theft (Form 106) DEA Report of drugs surrendered (From 41) DEA SCHEDULES: Schedule I Schedule II Schedule III Schedule IV Schedule V INTRODUCTION State and Federal regulations have been promulgated concerning the use and handling of US Department of Justice Drug Enforcement Administration (DEA) controlled substances. These regulations are in place to address materials which are or have the potential to be addictive or habit forming. These substances have been categorized into “schedules” that have been created by the DEA to reflect their level of concern. The “Carnegie Mellon University DEA Controlled Substances Program” is intended to ensure that Carnegie Mellon University is in compliance with our regulatory requirements. Required activities under the DEA include: 1. Registration of your work with the DEA and with Carnegie Mellon’s Department of Environmental Health and Safety (EH&S).
    [Show full text]
  • Chapter 329 [New] Uniform Controlled Substances Act
    CHAPTER 329 [NEW] UNIFORM CONTROLLED SUBSTANCES ACT Part I. General Provisions Section 329-1 Definitions 329-2 Hawaii advisory commission on drug abuse and controlled substances; number; appointment 329-3 Annual report 329-4 Duties of the commission Part II. Standards and Schedules 329-11 Authority to schedule controlled substances 329-12 Nomenclature 329-13 Schedule I tests 329-14 Schedule I 329-15 Schedule II tests 329-16 Schedule II 329-17 Schedule III Tests 329-18 Schedule III 329-19 Schedule IV tests 329-20 Schedule IV 329-21 Schedule V tests 329-22 Schedule V 329-23 Republishing and distribution of schedules Part III. Regulation of Manufacture, Distribution, Prescription, and Dispensing of Controlled Substances 329-31 Rules 329-31.5 Clinics 329-32 Registration requirements 329-33 Registration 329-34 Revocation and suspension of registration 329-35 Order to show cause 329-36 Records of registrants 329-37 Filing requirements 329-38 Prescriptions 329-39 Labels 329-40 Methadone treatment programs Part IV. Offenses and Penalties 329-41 Prohibited acts B-penalties 329-42 Prohibited acts C-penalties 329-43 Penalties under other laws 329-43.5 Prohibited acts related to drug paraphernalia Amended 0612 1 329-44 Notice of conviction to be sent to licensing board, department of commerce and consumer affairs 329-45 Repealed 329-46 Prohibited acts related to visits to more than one practitioner to obtain controlled substance prescriptions 329-49 Administrative penalties 329-50 Injunctive relief Part V. Enforcement and Administrative Provisions 329-51 Powers of enforcement personnel 329-52 Administrative inspections 329-53 Injunctions 329-54 Cooperative arrangements and confidentiality 329-55 Forfeitures 329-56 Burden of proof; liabilities 329-57 Judicial review 329-58 Education and research 329-59 Controlled substance registration revolving fund; established Part VI.
    [Show full text]
  • (Ph OH N N Me O YO O YO
    US 20070265293A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2007/0265293 A1 Boyd et al. (43) Pub. Date: Nov. 15, 2007 (54) (S)-N-METHYLNALTREXONE Publication Classification (76) Inventors: Thomas A. Boyd, Grandview, NY (51) Int. Cl. (US); Howard Wagoner, Warwick, NY A6II 3L/4355 (2006.01) (US); Suketu P. Sanghvi, Kendall Park, A6M II/00 (2006.01) NJ (US); Christopher Verbicky, A6M I5/08 (2006.01) Broadalbin, NY (US); Stephen 39t. 35O C Andruski, Clifton Park, NY (US) (2006.01) A6IP 3L/00 (2006.01) Correspondence Address: St. 4. CR WOLF GREENFIELD & SACKS, P.C. (2006.01) 6OO ATLANTIC AVENUE 3G (i. 308: BOSTON, MA 02210-2206 (US) A6IP 33/02 (2006.01) C07D 489/00 (2006.01) (21) Appl. No.: 11/441,452 (52) U.S. Cl. .............. 514/282; 128/200.23; 128/202.17; (22) Filed: May 25, 2006 546/45 Related U.S. Application Data (57) ABSTRACT This invention relates to S-MNTX, methods of producing (60) Provisional application No. 60/684,570, filed on May S-MNTX, pharmaceutical preparations comprising 25, 2005. S-MNTX and methods for their use. O G M Br Br e (pH OH N N Me O YO O YO OH OH R-MNTX S-MNTX Patent Application Publication Nov. 15, 2007 Sheet 1 of 6 US 2007/0265293 A1 Fig. 1 OH OH Me-N Me-N D / O O -----BBr, O O CHCI NMP, 3 AUTOCLAVE, 70'C OMe OH 1 2 Br OH As GE) G As 69 GOH Me-N ION Me-N -lass O SO EXCHANGE O SO OH OH 3 S-MNTX 1 - OXYCODONE 2 - OXYMORPHONE 3 - ODIDE SALT OF S-MNTX Fig.
    [Show full text]